Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04208100 · ClinicalTrials.gov registry record · NA
Pilot Evaluation of the Lutronic PicoPlus System for the Treatment of Benign Pigmented Lesions of the Hands
A NA study of Benign Pigmented Lesions, sponsored by CynosureLutronic.
- Active
- Registry status
- NA
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT04208100: Active NA study of Benign Pigmented Lesions, sponsored by CynosureLutronic.
NCT04208100 is a NA study of Benign Pigmented Lesions that is active but no longer recruiting, run by CynosureLutronic. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04208100, a NA study of Benign Pigmented Lesions, is active but no longer recruiting, sponsored by CynosureLutronic.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, multi-site, non-randomized study of up to 40 treated subjects; subjects enrolled may be greater than subjects treated.
Primary Outcome
Percentage of pigmentary clearance by each wavelength in standard photographs from the 30-day visit post the last treatment in Phase I of the study using a score of 0-4, representing poor 0-24%, fair 25-49%, good 50-74%, excellent 75-95%, and complete 95%+ improvement was given at the day 30 follow-up visit post the last treatment as determined by three blinded physician evaluators comparing the baseline vs 30-day follow-up visit photographs.
Conditions Studied
Interventions
- DEVICE PicoPlus
Study Locations (1)
Massachusetts
- William LoVerme, MD - Billerica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-09-13 |
| Est. Completion | 2020-03-31 |
| Phase | NA |
What the registry record for NCT04208100 still lists
NCT04208100 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Benign Pigmented Lesions appearing as the primary indexed condition, and to 1 intervention - of which PicoPlus is the first listed.
NCT04208100 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04208100 about?
NCT04208100 is a clinical study titled "Pilot Evaluation of the Lutronic PicoPlus System for the Treatment of Benign Pigmented Lesions of the Hands". Prospective, multi-site, non-randomized study of up to 40 treated subjects; subjects enrolled may be greater than subjects treated.
What is the current status of trial NCT04208100?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 41 participants. The study started on 2018-09-13. Estimated completion is 2020-03-31.
What conditions does trial NCT04208100 study?
This clinical trial studies the following conditions: Benign Pigmented Lesions.
What interventions are being tested in trial NCT04208100?
The interventions under investigation include: PicoPlus (DEVICE).
Who is sponsoring clinical trial NCT04208100?
This trial is sponsored by CynosureLutronic, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04208100 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Pigmented Lesions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04208100's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI